KNSA Stock Summary and Trading Ideas (Kiniksa Pharmaceuticals International PLC - Class A | NASDAQ:KNSA)

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Kiniksa Pharmaceuticals International PLC - Class A trades on the NASDAQ stock market under the symbol KNSA.

As of August 25, 2026, KNSA stock price climbed to $80.20 with 369,484 million shares trading.

KNSA has a beta of 0.08, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.00 to the broad based SPY ETF.

KNSA has a market cap of $6.26 billion. This is considered a Mid Cap stock.

Last quarter Kiniksa Pharmaceuticals International PLC - Class A reported $244 million in Revenue and $.30 earnings per share. This beat revenue expectation by $17 million and met earnings estimates .

In the last 3 years, KNSA traded as high as $82.94 and as low as $14.12.

The top ETF exchange traded funds that KNSA belongs to (by Net Assets): VTI, IWM, VB, VBK, IWO.

KNSA has outperformed the market in the last year with a price return of +137.6% while the SPY ETF gained +19.9%. KNSA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +50.6% and +4.8%, respectively, while the SPY returned +3.0% and -0.9%, respectively.

KNSA support price is $77.65 and resistance is $81.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.